ライフサイエンスコーパス: fat mass

1 ated endpoints (body mass index, weight, and fat mass).

2 esis of metabolic disorders linked to excess fat mass.

3 educed waist circumference, body weight, and fat mass.

4 sm while limiting formation and expansion of fat mass.

5 ons between metabolites and maternal BMI and fat mass.

6 early childhood and particularly with higher fat mass.

7 ght homeostat ("gravitostat") that regulates fat mass.

8 analysis, adjusted for sex, age, height, and fat mass.

9 hed when values are normalised to whole-body fat mass.

10 greater accretion of lean mass, rather than fat mass.

11 smaller infant birth size and less abdominal fat mass.

12 han that of control subjects, as well as low fat mass.

13 sue factor, which positively correlated with fat mass.

14 en HSMs, adjusting for age, height, lean and fat mass.

15 female mice is due to the reduction in body fat mass.

16 f inflammatory markers despite their greater fat mass.

17 tivity in adipose tissue and negatively with fat mass.

18 eight gain is associated with an increase in fat mass.

19 ass and glycolytic muscle fibers and reduced fat mass.

20 ative Hawaiian women, independently of total fat mass.

21 itions, physical activity, and 5-y change in fat mass.

22 in Models 1-4: 19-21%), C-peptides (23-25%), fat masses (0.48-0.60 kg), and fat-free masses (0.50-0.7

23 olesterol concentrations (0.05-0.09 mmol/L), fat masses (0.60-0.64 kg), and fat-free masses (0.35-0.4

24 global cognition function (0.17 to 0.23 SD), fat mass (-0.65 to -0.75 kg), physical function measures

25 G participants, as well as a greater loss of fat mass (-0.9 kg [95% CI -1.7 to -0.1], p = 0.029).

26 placebo was associated with decreased trunk fat mass (-0.9 kg, 95% CI -1.6 to -0.3, p = 0.0073), dec

27 6 to -0.3, p = 0.0073), decreased whole-body fat mass (-1.8 kg, 95% CI -2.9 to -0.7, p = 0.0016), and

28 nates had a nonsignificant increase in total fat mass (103.2 g, 95% CI -3.91 to 210.31, p = 0.06) and

29 taneous fat mass (1650-1850 cm(3)), visceral fat mass (1350-1650 cm(3)), and total body weight (11-12

30 umference (11-13 cm), abdominal subcutaneous fat mass (1650-1850 cm(3)), visceral fat mass (1350-1650

31 ean mass (-0.7 +/- 0.1 kg), and appendicular fat mass (-2.6 +/- 0.2 kg) each decreased.

32 .6 +/- 2.2 kg/m), LBM (-2.5 +/- 8.7 kg), and fat mass (-3.4 +/- 5.8 kg) was evident from preoperative

33 control group, of which 71% (mean change in fat mass 5.3 kg [SE 0.3] divided by mean change in weigh

34 8 +/- 3.6 vs. 34.9 +/- 4.8 g; P < 0.001) and fat mass (5.2 +/- 1.2 vs. 11.3 +/- 4.5 g; P < 0.001) of

35 body lean mass (-1.0 +/- 0.2 kg), whole-body fat mass (-6.9 +/- 0.5 kg), appendicular lean mass (-0.7

36 an adjusted 1.3 points lower percentage body fat mass (95% CI: -2.2, -0.4; P = 0.005) and an adjusted

37 utilization, contributing to lipogenesis and fat mass accumulation during positive energy balance.

38 onversely, ablation of Agrp neurons impaired fat mass accumulation.

39 exposure increased food intake, body weight, fat mass, adiposity, and whole-body glucose intolerance

40 bers listed in them for the decile values of fat mass and appendicular skeletal muscle mass utilizing

41 , whereas long-term leptin treatment reduces fat mass and body weight, and transiently alters circula

42 composition measurements revealed increased fat mass and decreased lean mass.

43 Body-fat mass and distribution, liver fat, and liver iron con

44 vivo, HSF1 antagonizes AMPK to control body fat mass and drive the lipogenic phenotype and growth of

45 induced reduction of sOb-R levels, increased fat mass and dyslipidemia, and hepatic steatosis in mice

46 Despite similar fat mass and energy balance, M(IL10) mice were protected

47 Thus, in PRADC1-deficient animals, decreased fat mass and enhanced physical activity are insufficient

48 We have also shown that fat mass and fasting glucose concentrations were lower i

49 lementation results in lower body weight and fat mass and higher lean mass in animals and adult human

50 (iBAT) thermogenesis accompanied by reduced fat mass and improved glucose/insulin homoeostasis.

51 ed food intake and body weight and preserved fat mass and lean mass during cachexia and LPS-induced a

52 BMD, fat mass and lean mass were collected from Dual-energy X

53 Fat mass and lean mass were measured using dual-energy-x

54 accompanied by marked increase in abdominal fat mass and metabolic abnormalities, including reductio

55 sed to improve bone quality while decreasing fat mass and metabolic dysfunction should lead to new st

56 rient and food profiles, may affect visceral fat mass and metabolic syndrome.

57 induced urinary glucose loss include reduced fat mass and more ketone bodies as additional fuel.

58 There were no associations with fat mass and no associations with any adolescent outcome

59 h body mass index, those in an intron of the fat mass and obesity-associated (FTO) gene have the larg

60 Fat mass and obesity-associated (FTO) gene is a candidat

61 Although the effect of the fat mass and obesity-associated (FTO) gene on adiposity

62 Noncoding polymorphisms in the fat mass and obesity-associated (FTO) gene represent com

63 cleotide polymorphism (SNP) rs3751812 in the fat mass and obesity-associated (FTO) gene was genotyped

64 The fat mass and obesity-associated gene (FTO) encodes an m6

65 Fat mass and obesity-associated gene (FTO) is a member o

66 The fat mass and obesity-associated gene (FTO) rs9939609 A-a

67 by decreased expression of adiponectin, the fat mass and obesity-associated gene, and the adiponecti

68 Mechanistically, R-2HG inhibits fat mass and obesity-associated protein (FTO) activity,

69 ethyladenosine (m(6)A) mRNA demethylation by fat mass and obesity-associated protein (FTO) increases

70 Fat mass and obesity-associated protein (FTO), an RNA N(

71 d that m(6)Am is selectively demethylated by fat mass and obesity-associated protein (FTO).

72 udies could prove a fundamental role of FTO (fat mass and obesity-associated protein) within obesity;

73 Here, we show that the FTO (fat mass and obesity-associated protein), an m6A demethy

74 transferase-like 3) and the demethylase FTO (fat mass and obesity-associated protein).

75 the best characterized RNA demethylase, FTO (fat mass and obesity-associated) in memory.

76 The fat mass and obesity-related (FTO) single-nucleotide pol

77 stemic insulin sensitivity, independently of fat mass and plasma HDL cholesterol.

78 fatty acids (PUFAs) to a rodent diet reduces fat mass and prevents the development of obesity, but ev

79 otball more than once a week for 1 year lost fat mass and reported improved mental health.

80 The coprimary end points were trunk fat mass and SF36 Physical Functioning score (SF36-PF) a

81 mice had a rapid increase in body weight and fat mass and specifically showed an increased number of

82 Both fat mass and the fat mass index were significantly lower

83 ght were assessed at ages 5 and 7 years, and fat mass and waist circumference at age 7.

84 und that NOD mice had approximately 50% less fat mass and were 2-fold more insulin sensitive, as meas

85 ned whether the disclosure of information on fat-mass and obesity-associated (FTO) genotype risk had

86 ts show increased food intake, enhanced body fat mass, and elevated plasma levels of triglycerides an

87 ght, waist circumference, hip circumference, fat mass, and fat-free mass were linearly related to inc

88 Adjustment for physical activity, diet, fat mass, and fatfree mass in addition to demographics a

89 ated donor mice reduced food consumption and fat mass, and increased adipose tissue leptin mRNA expre

90 emale mice, NNMT-ASO-KD reduced body weight, fat mass, and insulin level and improved glucose toleran

91 ted with albuminuria and with increased RPF, fat mass, and insulin resistance.

92 tio to albuminuria, renal plasma flow (RPF), fat mass, and insulin sensitivity (M/I).

93 reduced body weight, food intake, whole-body fat mass, and intramuscular triglycerides compared with

94 mma2(RG) mice exhibited reduced body weight, fat mass, and liver steatosis when fed with a high fat d

95 clinically modest, benefits on body weight, fat mass, and markers of oxidative stress and inflammato

96 the observed beneficial changes in visceral fat mass, and metabolomic and transcriptomic profiles di

97 ain, there are limited data on its impact on fat mass, and to our knowledge, the contribution of gene

98 lunted body-weight gain over time, had lower fat mass, and were more glucose tolerant than wild type

99 ivors have lower testosterone levels, higher fat mass, and worse quality of life (QoL) than age-match

100 ly increased body mass, overall and visceral fat masses, and decreased bone area.

101 The fat mass- and obesity-associated protein (FTO) is an m(6

102 Patients with higher visceral fat mass are at a higher risk of developing severe compl

103 ss and resting metabolic rate (RMR), but not fat mass, are strong predictors of energy intake (EI).

104 fat mass ratio, and abdominal preperitoneal fat mass area (P< 0.05) but not with childhood BMI.

105 hildhood BMI and the abdominal preperitoneal fat mass area.

106 selves against water shortage is to increase fat mass as a means for providing metabolic water.

107 The fat mass at 3M-PP was positively associated with PPWR at

108 ss was greatest in those with a high truncal fat mass at baseline.

109 Median fat mass at day 2 was 0.35 kg (interquartile range, 0.25

110 surements of fat distribution, such as total fat mass at DXA, visceral and subcutaneous adipose tissu

111 to determine the correlation of BMI or body fat mass (BFM) with blood pressure, fasting blood glucos

112 omes were a change from baseline in absolute fat mass, body weight, plasma F2-isoprostane concentrati

113 ubjects was without effect on body weight or fat mass, but improved several measures of glucose homeo

114 In this study, we tested whether the loss of fat mass by dietary restriction would remove the major s

115 id ratio, and preperitoneal and subcutaneous fat mass by physical examinations, dual-energy x-ray abs

116 norhabditis elegans results in animals whose fat mass can be modulated by exposure to light, despite

117 Differential effects on fat mass (CD: +2%; TRF: -2% to -4%; TRFHMB: -4% to -7%)

118 sity had higher baseline body mass index and fat mass compared with lower genetic risk peers, and the

119 ue mass increased by a median of 1.59 kg and fat mass decreased by a median of 1.52 kg in the exercis

120 improved (P < 0.001), and body and visceral fat mass decreased in all groups (P < 0.001).

121 feeding, Gpr119(-/-) mice exhibited reduced fat mass, decreased levels of circulating adipokines, im

122 increased lean mass and strength, decreased fat mass, deepening of the voice, increased sexual desir

123 ferences at discharge between RUTF groups in fat mass [Delta = 0.3 kg (95% CI: -0.6, 1.6 kg);P= 0.341

124 muciniphila enhanced its capacity to reduce fat mass development, insulin resistance and dyslipidemi

125 137, 469 g) than breastfed infants, but not fat mass (difference: -42 g; 95% CI: -299, 215 g).Formul

126 However, increased fat mass does not fully explain obesity's propensity to

127 In conclusion, obesity and high abdominal fat mass doubles the risk of psoriasis, and long-term we

128 Persistently high fat mass during adolescence was associated with greater

129 ssue exactly compensated for the decrease in fat mass during weight loss.

130 sses, dual-energy X-ray absorptiometry (DXA) fat mass, DXA lean mass, height z score, and IGF-I conce

131 A low-calorie diet (LCD) reduces fat mass excess, improves insulin sensitivity, and alter

132 ternal adiposity (recommended: -2.5+/-0.8 kg fat mass, excess: +2.2+/-0.5, inadequate: -4.5+/-0.5, P<

133 ulin-signaling pathway, which contributed to fat mass expansion, as well as a shift toward an anti-in

134 nced a ~73% reduction (~0.69 kg) in visceral fat mass (false discovery rate, FDR < 2.0 x 10(-16)), ac

135 d control mice in: body composition (lean or fat mass); fasting serum insulin; HbA1c; glucose dynamic

136 atterns were observed for obesity risk, body fat mass, fat percentage, fat mass index, and waist circ

137 ations between body mass index (in kg/m(2)), fat mass, fat-free mass, and RMR with acute (1 meal) and

138 Growth rates, fat mass, fat-free mass, and several essential amino aci

139 Repeated measures included weight, fat mass, fat-free mass, midupper arm circumference, tri

140 fic genetic correlations amongst body fat %, fat mass, fat-free mass, physical activity, glycemic tra

141 ants in the coffee arm experienced a loss of fat mass (FM) (-3.7%; 95% CI: -6.3, -1.1%; P = 0.006) an

142 olic disease, but the relative importance of fat mass (FM) and fat-free mass (FFM) accretion is not w

143 Weight, height, and BC [fat mass (FM) and lean mass (LM) by DXA] were measured (

144 Measurements of maternal fat mass (FM) are important for studies of maternal and

145 body weight (TBW), fat-free mass (FFM), and fat mass (FM) on left ventricular (LV) geometry and func

146 ing the extent to which they correspond with fat mass (FM) or fat-free mass (FFM) during infancy.This

147 o median BMI, PAL, and sex-specific ratio of fat mass (FM) to fat-free mass (FFM).

148 ombined to calculate fat-free mass (FFM) and fat mass (FM) using equations based on the Reference Chi

149 Fat-free (FFM) and fat mass (FM) were determined by deuterium dilution and

150 mass (LBM), skeletal muscle index (SMI), and fat mass (FM) were determined pre-treatment, preoperativ

151 l function, muscle strength, lean mass (LM), fat mass (FM), bone mineral content (BMC), muscle cross-

152 o included body weight, waist circumference, fat mass (FM), fat-free mass (FFM), and appendicular mas

153 ectional reference values were generated for fat mass (FM), fat-free mass (FFM), and percentage body

154 aseline measures and longitudinal changes in fat mass (FM), lean mass (LM), and waist circumference (

155 ipoprotein (HDL) cholesterol, triglycerides, fat mass (FM), systolic and diastolic blood pressure, fa

156 all improvement in both BMI (-0.9+/-0.6) and fat mass (FM: -2.3+/-1.5), while lean body mass was pres

157 Concurrently, fat mass, food intake (FI), and ucp1 expression in brown

158 l body mass index (BMI) on offspring BMI and fat mass from childhood to early adulthood.

159 ody size was associated with less weight and fat mass gain (r = -0.78, P = 0.04) and with the increas

160 d also promotes age-related and diet-induced fat mass gain and insulin resistance.

161 ions significantly inhibited body weight and fat mass gain compared to animals fed an HFD continuousl

162 energy expenditure (EE) predicts weight and fat mass gain in this population.

163 luence high fat diet-induced body weight and fat mass gain throughout the study.

164 sity measured as HFD-induced body weight and fat mass gain, or metabolism of glucose and insulin tole

165 oving glucose tolerance and modestly slowing fat mass gain.

166 odestly improves glucose tolerance and slows fat mass gain.

167 t engage in regular PA exhibited higher BMI, fat mass, HC, and WC with statistical significance (P <

168 ee or more risk factors out of high visceral fat mass, high blood pressure, low high-density-lipoprot

169 elated traits, including body-mass index and fat mass, hypertension and lung function, even after adj

170 established; it leads to decreased body and fat mass, improved glucose homeostasis and extended life

171 rienced weight loss, persistent reduction in fat mass, improvements in metabolic profile, and decreas

172 circumference, skinfold thickness, and body fat mass in 1,301 children from six European birth cohor

173 isms underlying the marked increase in total fat mass in 6-month-old mutants.

174 association of uMg with fasting insulin and fat mass in a general population.

175 Prenatal phthalate exposures and childhood fat mass in a New York City cohort.

176 n prenatal phthalate exposures and childhood fat mass in a prospective cohort study.

177 lower BMI z-score, waist circumference, and fat mass in boys during early childhood.

178 er, the data show that the increase in total fat mass in Cc1(-/-) mice is mainly attributed to hyperp

179 l DEHP exposure may be associated with lower fat mass in childhood.

180 s was positively correlated with the percent fat mass in infants (r = 0.475; P < 0.05).

181 ght and ultimately resulted in a doubling of fat mass in males and females.

182 ation years is more strongly correlated with fat mass in males.

183 The expansion of fat mass in the obese state is due to increased adipocyt

184 Analysis of body mass index z score and fat mass in the same cohort highlighted inconsistent est

185 e associations between flavonoid intakes and fat mass.In a study of 2734 healthy, female twins aged 1

186 of dual-energy X-ray absorptiometry-derived fat mass included the limb-to-trunk fat mass ratio (FMR)

187 early onset insulin resistance and visceral fat mass increase, contributing to accelerated body weig

188 , that MC3R(hDM/hDM) have greater weight and fat mass, increased energy intake and feeding efficiency

189 MR and LR decreased body and fat mass, increased food intake, elevated lipid cycling

190 esized that organ fat, rather than the total fat mass, increases the risk of asthma.Methods: In a pop

191 proanthocyanidins, are associated with lower fat mass independent of shared genetic and common enviro

192 ied homeostat for body weight regulates body fat mass independently of fat-derived leptin, revealing

193 (beta = -0.006, 95%CI: -0.009; -0.003), and fat mass index (beta = -0.015, 95%CI: -0.021; -0.009), i

194 as independently associated only with higher fat mass index (beta = 0.003, 95%CI: 0.001; 0.005).

195 At age 6 y, fat mass index (FMI) and fat-free mass index (FFMI) were

196 At 6 y of age, we further measured fat mass index (FMI) and fat-free mass index with dual-e

197 The fat mass index (FMI) and lean mass index (LMI) were surr

198 Fat-free mass index (FFMI) and fat mass index (FMI) are superior to BMI and fat percent

199 ents [0.005-0.05 z-score units and 0.02-0.45 fat mass index (FMI) or fat-free mass index units per un

200 ss index-standard deviation score (BMI-SDS), fat mass index (FMI), body fat % (BF%), and waist circum

201 index z-scores (BMIZ) at 5 and 7 years, and fat mass index (FMI), percent body fat (%BF), and waist

202 The primary outcome was fat mass index (FMI), whereas the secondary outcomes wer

203 to model the relationship between predicted fat mass index (FMI, adipose tissue (kg)/height (m)2), l

204 = 0.3 kg (95% CI: -0.6, 1.6 kg);P= 0.341] or fat mass index [Delta = 0.4 kg/m(2)(95% CI: -0.3, 1.1 kg

205 energy X-ray absorptiometry [DXA] determined fat mass index [FMI]) in a MR approach.

206 ed general fat including body mass index and fat mass index by dual-energy X-ray absorptiometry, and

207 /m(2) (95% CI: -0.02, 0.36) higher DXA total fat mass index in mid-childhood.

208 Increasing fat mass index trajectories were associated with lower l

209 c body mass index, lean body mass index, and fat mass index trajectories were developed using Group-B

210 A high fat mass index was associated with a higher Rint (Z scor

211 and Main Results: Higher body mass index and fat mass index were associated with higher FEV(1) (z-sco

212 Both fat mass and the fat mass index were significantly lower in the GUMLi gro

213 waist circumference, visceral abdominal fat, fat mass index, and android/gynoid fat ratio were the ou

214 uded the limb-to-trunk fat mass ratio (FMR), fat mass index, and central fat mass index.In cross-sect

215 obesity risk, body fat mass, fat percentage, fat mass index, and waist circumference, but not for fat

216 was associated with lower blood pressure and fat mass index, and with more physical activity.

217 6178 children aged 6 years, we measured BMI, fat mass index, android/gynoid ratio, and preperitoneal

218 rdiometabolic risk factors (body mass index, fat mass index, blood pressure, physical activity, smoki

219 Higher visceral fat index, independent of fat mass index, was associated with higher FVC (z-score

220 ass ratio (FMR), fat mass index, and central fat mass index.In cross-sectional multivariable analyses

221 We used total and trunk fat mass indices (FMIs) to classify participants as norm

222 on at 15 years in both sexes, whereas higher fat mass is associated with lower levels of only some lu

223 Decreased fat mass is attributed, in part, to increased metabolic

224 Sex-specific centiles for fat mass (kg), fat-free mass (kg), and percentage body f

225 bioelectrical impedance-derived measures of fat mass, lean body mass, and fat percentage.

226 ey filtration, percentage body fat, visceral fat mass, lean body mass, cardiopulmonary fitness, physi

227 Body composition, including fat mass, lean mass, bone mineral content, and bone mine

228 show that despite increased body weight and fat mass, LFABP(-/-) mice are protected from a high-fat

229 rans-retinoic acid (ATRA) on body weight and fat mass, lipid metabolism, and retinoic acid signaling

230 ic and acute muscle MPC deletion accelerated fat mass loss on a normal diet after high fat diet-induc

231 show that a reduced BCAA diet promotes rapid fat mass loss without calorie restriction in obese mice.

232 d by mean change in weight 7.5 kg [0.4]) was fat mass loss.

233 een races and was positively correlated with fat-mass loss, but not with weight regain, overall.

234 ce -0.1 kg, 95% CI -1.9 to 1.6 kg, p = 0.87; fat mass mean difference 1.2 kg, 95% CI -0.6 to 3.0 kg,

235 s 15.6% respectively, p=0.123), reduction in fat mass (mean difference -1.537kg [-2.947 to -0.127], p

236 5.6%, respectively, P = 0.123), reduction in fat mass (mean difference, -1.537 kg; 95% CI, -2.947 to

237 netic risk peers, and they gained weight and fat mass more rapidly during follow-up.

238 tio, 2.99; 99% CI, 1.35-6.59; P = .0004) and fat mass of the 80th percentile or greater at day 2 (adj

239 Moreover, BW gain and total fat masses of usually superobese ob/ob mice were signifi

240 ases hepatic NAD(+) levels without affecting fat mass or glucose tolerance in HNKO or WT animals.

241 Fenugreek did not alter body weight, fat mass, or food intake in either group, but did transi

242 o PF after adjustment for lean body mass and fat-mass ( P = 0.001 and 0.007, respectively).

243 ipose interleukin-6 messenger RNA levels and fat mass (p < 0.001; R = 0.64 and 0.89).

244 ere eradicated when normalised to whole-body fat mass (P = 0.416).

245 ed exclusively by associations with visceral fat mass (P=0.002), with no association seen between Del

246 iated with a tendency for a higher abdominal fat mass percentage (quartile 4 compared with quartile 1

247 offspring and a tendency for a higher total fat mass percentage among male offspring (quartile 4 com

248 0.001, 0.01 < eta(2) < 0.14) for whole body fat mass percentage and index of low muscle mass.

249 ), daily sedentary time, body-mass index, or fat mass percentage between participants who had moved t

250 easured childhood body mass index (BMI), the fat mass percentage, and the android:gynoid fat ratio wi

251 After multivariate analyses, only a lower fat mass persisted as a risk factor for vertebral fractu

252 ponse may be an early defect with increasing fat mass, potentially dependent on altered anabolic sign

253 , which is likely due to alterations of both fat mass quantity and qualitative changes, including a r

254 P = 0.03), RPF (r = -0.52, P = 0.0009), and fat mass (r = -0.33, P = 0.02).

255 ined less weight (r = -0.84, P = 0.03), less fat mass (r = -0.81, P = 0.049), and stored less calorie

256 t mass R2 = 0.88 male, 0.93 female; visceral fat mass R2 = 0.67 male, 0.75 female.

257 3DO body composition accuracy to DXA was: fat mass R2 = 0.88 male, 0.93 female; visceral fat mass

258 with reduced levels of BCAAs lost weight and fat mass rapidly until regaining a normal weight.

259 -derived fat mass included the limb-to-trunk fat mass ratio (FMR), fat mass index, and central fat ma

260 dy fat percentage and a lower android:gynoid fat mass ratio (P< 0.05) but not with childhood BMI and

261 A high android/gynoid fat mass ratio was associated with a lower Feno (Sym% [9

262 od total-body fat percentage, android:gynoid fat mass ratio, and abdominal preperitoneal fat mass are

263 Throughout the intervention, fat mass reduced significantly in the PRO group and ther

264 r is critical for weight loss, anorexia, and fat mass reduction induced by central GLP-1R activation.

265 wo independent negative feedback systems for fat mass regulation.

266 ain, weight, the percentage of body fat, and fat mass remained significantly reduced from baseline th

267 We evaluated the ability of the Relative Fat Mass (RFM) to estimate whole-body fat percentage amo

268 n models for SIClamp (P < 0.05); higher BMI, fat mass, SAAT, leg fat, and liver fat were associated w

269 ter adjusting for gains in fat-free mass and fat mass, SMR increased by 43 +/- 123 kcal/d more than e

270 e individuals are proportional to whole-body fat mass, suggesting a compensatory down-regulation, pre

271 en consumption and decreased body weight and fat mass, suggesting an increased energy cost of cold ad

272 The PRO group had a greater loss of fat mass than did the CON group (PRO: -4.8 +/- 1.6 kg; C

273 chieves greater reduction in body weight and fat mass than monotherapies by promoting negative energy

274 sed to 0.8 ppm ozone had lower lean mass and fat mass than pooled control offspring.

275 For each sex and measure (e.g., fat mass), the new charts comprised 2 panels.

276 mainly by visceral fat, independent of total fat mass; therefore, abdominal fat might contribute to a

277 alate metabolite concentrations with percent fat mass using linear mixed-effects regression models wi

278 and diet have been shown to impact visceral fat mass (VFM), a major risk factor for cardiometabolic

279 en at age 8 (6-11) years were assessed: BMI, fat mass, waist circumference, and skinfold thickness.

280 Fat mass was 3.06% (95% CI: -5.99, -0.09%) lower among c

281 and waist circumference measurements whereas fat mass was assessed using repeated dual-energy x-ray a

282 16.3 to -3.4]), whereas a high preperitoneal fat mass was associated with a higher Feno (Sym% [95% CI

283 timated by blood oxygen level-dependent MRI; fat mass was estimated by DXA; GFR and RPF were estimate

284 Decrease in fat mass was greatest in those with a high truncal fat m

285 Fat mass was measured with dual-energy x-ray absorptiome

286 Although whole-body fat mass was not affected, visceral adipose tissue mass

287 Subcutaneous fat mass was not associated with any respiratory outcome

288 Total fat mass was positively associated with PWV at age 17 ye

289 Fat mass was quantified with computed tomography imaging

290 Weight increase (both lean and fat mass) was greatest in the TAF-based group and among

291 ceral cavity, and liver, adjusting for total fat mass; we evaluated the association of adult weight c

292 urinary phthalate concentrations and percent fat mass were modified by child's sex.

293 in promoting increases in LBM and losses of fat mass when combined with a high volume of resistance

294 onfounded by differences in lean mass versus fat mass when modeled on weight.

295 ce gained significantly less body weight and fat mass when on high-fat diets compared with littermate

296 circumference and for fat-free mass than for fat mass, which was explained largely by height.

297 reted LCN2 suppresses appetite and decreases fat mass while improving glucose metabolism.

298 uced obese mice lacking lncOb show increased fat mass with reduced plasma leptin levels and lose weig

299 and higher education as causal for decreased fat mass, with higher body fat % possibly being a causal

300 eases nutrient oxidation, and decreases body fat mass without altering food intake, lean body mass, b